Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.
- 05 Sep 2018 Planned initiation date changed from 1 Aug 2018 to 1 Nov 2018.
- 03 Jul 2018 Planned initiation date changed from 15 Jun 2018 to 1 Aug 2018.